Myasthenia gravis (MG) develops when autoantibodies against the acetylcholine receptor cause a breakdown in communication between nerves and muscles.
The resulting weakness and rapid fatigue of skeletal muscles can occur in multiple muscle groups, which is known as generalized MG and is by far the most common form of the disease.
Dr Henry Kaminski from George Washington University discusses how the management of generalized MG has evolved, leading to the introduction of biologic therapies.
He focuses on the complement inhibitor eculizumab as well as neonatal Fc receptor inhibitors, including efgartigimod, which was recently approved for use in MG by the US Food and Drug Administration.
Dr Kaminski comments that the optimal role of these therapies will evolve, but currently they offer important options for patients who have had inadequate response to other therapies.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Biologic Therapies in Myasthenia Gravis - Medscape - May 24, 2022.
Comments